kir6 2  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88

    Structured Review

    Alomone Labs kir6 2
    Relative expression of Kir6.1, <t>Kir6.2,</t> SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P
    Kir6 2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kir6 2/product/Alomone Labs
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kir6 2 - by Bioz Stars, 2022-01
    88/100 stars

    Images

    1) Product Images from "Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With Age"

    Article Title: Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With Age

    Journal: Journal of Cardiovascular Pharmacology

    doi: 10.1097/FJC.0000000000000394

    Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P
    Figure Legend Snippet: Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P

    Techniques Used: Expressing

    2) Product Images from "Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions"

    Article Title: Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions

    Journal: Journal of Neurotrauma

    doi: 10.1089/neu.2017.5619

    Kir6.2 expression in neurons, glial cells, and microglia. From left to right, representative box plots of Kir6.2 expression in neurons (percentage), in glial cells, and microglia (semi-quantitative scale from 0 to 3). The results show a significantly increased expression of Kir6.2 in glial cells from contusion samples (Wilcoxon rank sum test; p = 0.03), but non-significant differences in neurons and microglia. Asterisks indicate statistically significant differences (* p ≤ 0.05).
    Figure Legend Snippet: Kir6.2 expression in neurons, glial cells, and microglia. From left to right, representative box plots of Kir6.2 expression in neurons (percentage), in glial cells, and microglia (semi-quantitative scale from 0 to 3). The results show a significantly increased expression of Kir6.2 in glial cells from contusion samples (Wilcoxon rank sum test; p = 0.03), but non-significant differences in neurons and microglia. Asterisks indicate statistically significant differences (* p ≤ 0.05).

    Techniques Used: Expressing

    Kir6.2 protein levels in control and contusion samples. (A) Box plots of Kir6.2 relative intensity in control and contusion samples, showing a significant increase of Kir6.2 expression ( p = 0.014) in contusion specimens; data normalized to β-actin loading controls. (B) Representative image of a western blot showing a clear difference between control and contusion samples.
    Figure Legend Snippet: Kir6.2 protein levels in control and contusion samples. (A) Box plots of Kir6.2 relative intensity in control and contusion samples, showing a significant increase of Kir6.2 expression ( p = 0.014) in contusion specimens; data normalized to β-actin loading controls. (B) Representative image of a western blot showing a clear difference between control and contusion samples.

    Techniques Used: Expressing, Western Blot

    Expression of Kir6.2 in different cell types. The first three columns of the montage show Kir6.2 expression in different cell types of the peri-contusional tissue and the last three show Kir6.2 expression in control tissue. Peri-contusional tissue: fluorescent double labeling for NeuN/ glial fibrillary acidic protein (GFAP)/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the third column. Control tissue: fluorescent double labeling for NeuN/GFAP/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the last column. In controls, the Kir6.2 expression was evident in neurons and microglia but was minimal in astrocytes (GFAP-positive cells). Original magnification = 100x. Scale: 20 μm. Nuclei were counterstained with 4,6-diamino-2-phenylindole (DAPI).
    Figure Legend Snippet: Expression of Kir6.2 in different cell types. The first three columns of the montage show Kir6.2 expression in different cell types of the peri-contusional tissue and the last three show Kir6.2 expression in control tissue. Peri-contusional tissue: fluorescent double labeling for NeuN/ glial fibrillary acidic protein (GFAP)/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the third column. Control tissue: fluorescent double labeling for NeuN/GFAP/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the last column. In controls, the Kir6.2 expression was evident in neurons and microglia but was minimal in astrocytes (GFAP-positive cells). Original magnification = 100x. Scale: 20 μm. Nuclei were counterstained with 4,6-diamino-2-phenylindole (DAPI).

    Techniques Used: Expressing, Labeling

    3) Product Images from "Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With Age"

    Article Title: Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With Age

    Journal: Journal of Cardiovascular Pharmacology

    doi: 10.1097/FJC.0000000000000394

    Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P
    Figure Legend Snippet: Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P

    Techniques Used: Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Alomone Labs kir6 2
    Relative expression of Kir6.1, <t>Kir6.2,</t> SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P
    Kir6 2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kir6 2/product/Alomone Labs
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kir6 2 - by Bioz Stars, 2022-01
    88/100 stars
      Buy from Supplier

    94
    Alomone Labs kir6 2 antibody
    <t>Kir6.2</t> expression in neurons, glial cells, and microglia. From left to right, representative box plots of Kir6.2 expression in neurons (percentage), in glial cells, and microglia (semi-quantitative scale from 0 to 3). The results show a significantly increased expression of Kir6.2 in glial cells from contusion samples (Wilcoxon rank sum test; p = 0.03), but non-significant differences in neurons and microglia. Asterisks indicate statistically significant differences (* p ≤ 0.05).
    Kir6 2 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/kir6 2 antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    kir6 2 antibody - by Bioz Stars, 2022-01
    94/100 stars
      Buy from Supplier

    90
    Alomone Labs antibodies against kir6 1
    Nico ameliorated LPS-induced ALI and inflammation. (a) Nico increased LPS-induced <t>Kir6.1</t> and Kir6.2 downregulation in the lung. (b, c) Lung sections stained with H E showed severe injury in the LPS group which was attenuated by Nico pretreatment. The data revealed a high score for the LPS-treated group which was decreased in the Nico-pretreated group. (d) Nico pretreatment significantly reduced LPS-induced protein leakage in BALF. (e, f) Nico alleviated LPS-induced increments of MPO activities in BALF and lung homogenate. (g, h) Nico prevented the production of TNF- α and IL-1 β in lung homogenate. Data were shown as mean ± SEM ( n = 6 − 8). Statistically significant differences: ∗ P
    Antibodies Against Kir6 1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against kir6 1/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against kir6 1 - by Bioz Stars, 2022-01
    90/100 stars
      Buy from Supplier

    Image Search Results


    Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P

    Journal: Journal of Cardiovascular Pharmacology

    Article Title: Altered KATP Channel Subunits Expression and Vascular Reactivity in Spontaneously Hypertensive Rats With Age

    doi: 10.1097/FJC.0000000000000394

    Figure Lengend Snippet: Relative expression of Kir6.1, Kir6.2, SUR2A, and SUR2B mRNA. A, Kir6.1, (B) SUR2B, (C) Kir6.2, and (D) SUR2A. Data shown are the means ± standard error of the mean of 6 separate experiments. * P

    Article Snippet: The primary antibody dilutions were 1:300 for Kir6.1 (ABcam, Britain), 1:500 for Kir6.2 (Alomone, Israel), 1:300 for SUR2B (Santa, Japan), and 1:30,000 for GAPDH (ABcam) antibodies.

    Techniques: Expressing

    Kir6.2 expression in neurons, glial cells, and microglia. From left to right, representative box plots of Kir6.2 expression in neurons (percentage), in glial cells, and microglia (semi-quantitative scale from 0 to 3). The results show a significantly increased expression of Kir6.2 in glial cells from contusion samples (Wilcoxon rank sum test; p = 0.03), but non-significant differences in neurons and microglia. Asterisks indicate statistically significant differences (* p ≤ 0.05).

    Journal: Journal of Neurotrauma

    Article Title: Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions

    doi: 10.1089/neu.2017.5619

    Figure Lengend Snippet: Kir6.2 expression in neurons, glial cells, and microglia. From left to right, representative box plots of Kir6.2 expression in neurons (percentage), in glial cells, and microglia (semi-quantitative scale from 0 to 3). The results show a significantly increased expression of Kir6.2 in glial cells from contusion samples (Wilcoxon rank sum test; p = 0.03), but non-significant differences in neurons and microglia. Asterisks indicate statistically significant differences (* p ≤ 0.05).

    Article Snippet: One of the membranes was incubated with our Kir6.2 antibody at a 1:10,000 dilution and the other one with the Kir6.1 antibody at a 1:200 dilution as recommended by the manufacturer.

    Techniques: Expressing

    Kir6.2 protein levels in control and contusion samples. (A) Box plots of Kir6.2 relative intensity in control and contusion samples, showing a significant increase of Kir6.2 expression ( p = 0.014) in contusion specimens; data normalized to β-actin loading controls. (B) Representative image of a western blot showing a clear difference between control and contusion samples.

    Journal: Journal of Neurotrauma

    Article Title: Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions

    doi: 10.1089/neu.2017.5619

    Figure Lengend Snippet: Kir6.2 protein levels in control and contusion samples. (A) Box plots of Kir6.2 relative intensity in control and contusion samples, showing a significant increase of Kir6.2 expression ( p = 0.014) in contusion specimens; data normalized to β-actin loading controls. (B) Representative image of a western blot showing a clear difference between control and contusion samples.

    Article Snippet: One of the membranes was incubated with our Kir6.2 antibody at a 1:10,000 dilution and the other one with the Kir6.1 antibody at a 1:200 dilution as recommended by the manufacturer.

    Techniques: Expressing, Western Blot

    Expression of Kir6.2 in different cell types. The first three columns of the montage show Kir6.2 expression in different cell types of the peri-contusional tissue and the last three show Kir6.2 expression in control tissue. Peri-contusional tissue: fluorescent double labeling for NeuN/ glial fibrillary acidic protein (GFAP)/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the third column. Control tissue: fluorescent double labeling for NeuN/GFAP/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the last column. In controls, the Kir6.2 expression was evident in neurons and microglia but was minimal in astrocytes (GFAP-positive cells). Original magnification = 100x. Scale: 20 μm. Nuclei were counterstained with 4,6-diamino-2-phenylindole (DAPI).

    Journal: Journal of Neurotrauma

    Article Title: Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions

    doi: 10.1089/neu.2017.5619

    Figure Lengend Snippet: Expression of Kir6.2 in different cell types. The first three columns of the montage show Kir6.2 expression in different cell types of the peri-contusional tissue and the last three show Kir6.2 expression in control tissue. Peri-contusional tissue: fluorescent double labeling for NeuN/ glial fibrillary acidic protein (GFAP)/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the third column. Control tissue: fluorescent double labeling for NeuN/GFAP/Iba1/CD31 (green) and Kir6.2 (red). Merged images are presented in the last column. In controls, the Kir6.2 expression was evident in neurons and microglia but was minimal in astrocytes (GFAP-positive cells). Original magnification = 100x. Scale: 20 μm. Nuclei were counterstained with 4,6-diamino-2-phenylindole (DAPI).

    Article Snippet: One of the membranes was incubated with our Kir6.2 antibody at a 1:10,000 dilution and the other one with the Kir6.1 antibody at a 1:200 dilution as recommended by the manufacturer.

    Techniques: Expressing, Labeling

    Confocal double immunofluorescence images of CD11b (red, A and D) and Kir6.2 (green, B and E) in spinal cord sections from healthy control mice (Ctrl) or MOG 35-55 EAE mice . A slight intensity was found for Kir6.2 in healthy section showing low localization of the K ATP Kir6.2 subunit in CD11b-positive cells (white arrows, C). However, higher intensity of Kir6.2 subunit in CD11b reactive cells showing a strong colocalization of both (white arrows, F) was observed. Western blotting for Kir6.2 in total protein homogenates from lumbar-sacral and thoracic-cervical regions of the spinal cord from non-immunized control animals (control, G) and EAE mice (EAE, G) show an increase in Kir6.2 expression in EAE mice. This increase is statistically significant in the thoracic-cervical level of the spinal cord (H). Results are shown as mean ± SEM. ** p

    Journal: Journal of Neuroinflammation

    Article Title: Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

    doi: 10.1186/1742-2094-8-149

    Figure Lengend Snippet: Confocal double immunofluorescence images of CD11b (red, A and D) and Kir6.2 (green, B and E) in spinal cord sections from healthy control mice (Ctrl) or MOG 35-55 EAE mice . A slight intensity was found for Kir6.2 in healthy section showing low localization of the K ATP Kir6.2 subunit in CD11b-positive cells (white arrows, C). However, higher intensity of Kir6.2 subunit in CD11b reactive cells showing a strong colocalization of both (white arrows, F) was observed. Western blotting for Kir6.2 in total protein homogenates from lumbar-sacral and thoracic-cervical regions of the spinal cord from non-immunized control animals (control, G) and EAE mice (EAE, G) show an increase in Kir6.2 expression in EAE mice. This increase is statistically significant in the thoracic-cervical level of the spinal cord (H). Results are shown as mean ± SEM. ** p

    Article Snippet: Cells were then incubated with primary antibodies anti-Kir6.1 and anti-Kir6.2 (1:300 dilution, Alomone, Jerusalem, Israel), anti-CD11b (1:500 dilution, Serotec, Oxford, England, UK) at 4°C overnight, followed by secondary antibodies Alexa®488 and 596 (1:500, Molecular Probes, Invitrogen, Eugene, OR, USA) for 1 h in blocking solution.

    Techniques: Immunofluorescence, Mouse Assay, Western Blot, Expressing

    Western blotting show expression of both Kir6.1 and Kir6.2 K ATP channel pore-forming subunits in unstimulated and LPS/IFNγ-stimulated BV-2 cells (A, left) and microglial primary cultures (A, Right). Staining for the microglial cell membrane marker CD11b (B and E) and the K ATP channel subunits Kir 6.1 (C) or Kir 6.2 (F) showed colocalization in BV-2 microglia, indicating the expression of the K ATP channel at the cytoplasmic membrane (D and G, white arrows) . Control: unstimulated cells; L+I: cells stimulated with LPS and IFNγ. Scale bar = 30 μm.

    Journal: Journal of Neuroinflammation

    Article Title: Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

    doi: 10.1186/1742-2094-8-149

    Figure Lengend Snippet: Western blotting show expression of both Kir6.1 and Kir6.2 K ATP channel pore-forming subunits in unstimulated and LPS/IFNγ-stimulated BV-2 cells (A, left) and microglial primary cultures (A, Right). Staining for the microglial cell membrane marker CD11b (B and E) and the K ATP channel subunits Kir 6.1 (C) or Kir 6.2 (F) showed colocalization in BV-2 microglia, indicating the expression of the K ATP channel at the cytoplasmic membrane (D and G, white arrows) . Control: unstimulated cells; L+I: cells stimulated with LPS and IFNγ. Scale bar = 30 μm.

    Article Snippet: Cells were then incubated with primary antibodies anti-Kir6.1 and anti-Kir6.2 (1:300 dilution, Alomone, Jerusalem, Israel), anti-CD11b (1:500 dilution, Serotec, Oxford, England, UK) at 4°C overnight, followed by secondary antibodies Alexa®488 and 596 (1:500, Molecular Probes, Invitrogen, Eugene, OR, USA) for 1 h in blocking solution.

    Techniques: Western Blot, Expressing, Staining, Marker

    Nico ameliorated LPS-induced ALI and inflammation. (a) Nico increased LPS-induced Kir6.1 and Kir6.2 downregulation in the lung. (b, c) Lung sections stained with H E showed severe injury in the LPS group which was attenuated by Nico pretreatment. The data revealed a high score for the LPS-treated group which was decreased in the Nico-pretreated group. (d) Nico pretreatment significantly reduced LPS-induced protein leakage in BALF. (e, f) Nico alleviated LPS-induced increments of MPO activities in BALF and lung homogenate. (g, h) Nico prevented the production of TNF- α and IL-1 β in lung homogenate. Data were shown as mean ± SEM ( n = 6 − 8). Statistically significant differences: ∗ P

    Journal: Oxidative Medicine and Cellular Longevity

    Article Title: Nicorandil Attenuates LPS-Induced Acute Lung Injury by Pulmonary Endothelial Cell Protection via NF-κB and MAPK Pathways

    doi: 10.1155/2019/4957646

    Figure Lengend Snippet: Nico ameliorated LPS-induced ALI and inflammation. (a) Nico increased LPS-induced Kir6.1 and Kir6.2 downregulation in the lung. (b, c) Lung sections stained with H E showed severe injury in the LPS group which was attenuated by Nico pretreatment. The data revealed a high score for the LPS-treated group which was decreased in the Nico-pretreated group. (d) Nico pretreatment significantly reduced LPS-induced protein leakage in BALF. (e, f) Nico alleviated LPS-induced increments of MPO activities in BALF and lung homogenate. (g, h) Nico prevented the production of TNF- α and IL-1 β in lung homogenate. Data were shown as mean ± SEM ( n = 6 − 8). Statistically significant differences: ∗ P

    Article Snippet: Then, the transferred membranes were incubated with primary antibodies against Kir6.1 (Alomone Labs, Jerusalem, Israel), Kir6.2 (Abcam), NF-κ B p-p65/p65, p-iκ B-α /iκ B-α , p-p38/p38, p-ERK/ERK, p-JNK/JNK, intercellular adhesion molecule-1 (ICAM-1), cleaved-caspase-3 (c-caspase-3), caspase-9 (1 : 1000, Cell Signaling Technology), endothelial nitric oxide synthase (eNOS) (1 : 1000, Santa Cruz), inducible nitric oxide synthase (iNOS) (1 : 1000, Millipore), CCAAT/enhancer-binding protein homologous protein (CHOP), vascular cell adhesion molecule-1 (VCAM-1), VE-cadherin, Nox4 (1 : 1000), MnSOD (1 : 5000, Abcam), and β -actin (1 : 5000, Proteintech, Rosemont, USA) overnight.

    Techniques: Staining